is oral semaglutide fda approved approval date approves first-ever GLP-1RA for obesity and chronic weight management. Meet Wegovy (semaglutide) tablets. https://www.prnewswire.com/news-releases/fda-approves -novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1 FDA Approves First Oral GLP-1

Semaglutide is most appropriate for patients with a BMI of 30 or higher, or those with a BMI of 27 or higher with weight-related health conditions such as type 2 diabetes, hypertension, or sleep apnea

Research shows clear benefits: Better stability than oral delivery, which exposes peptides to harsh stomach conditions Less breakdown by enzymes that would destroy the peptide before it reaches the blood Easier compliance no needles, no mixing, just spray Potential for targeted delivery to specific tissues, including the brain via the olfactory pathway Nasal delivery works very well for peptides like BPC-157 that target the whole body

Most studies used a placebo as the control treatment, though a few compared GLP-1RAs with other medications or behavioral therapies

Who should avoid AHK-Cu Individuals with copper metabolism disorders, specifically Wilson disease or Menkes disease, should not use copper peptides without medical guidance

Wait 20 minutes before eating

10.1371/journal.pone.0101364 291 WhitleyR.LakemanA.NahmiasA.RoizmanB